Zimlovisertib、Ritlecitinib和Tofacitinib单独或联合治疗中重度类风湿关节炎和甲氨蝶呤反应不足患者的疗效和安全性

IF 11.4 1区医学 Q1 RHEUMATOLOGY

Arthritis & Rheumatology Pub Date : 2025-04-14 DOI:10.1002/art.43184

Spencer I. Danto, Mikhail Salganik, Anindita Banerjee, Pawel Hrycaj, Irina Jashi, Negin Shojaee, Ravi Shankar P. Singh, Steven A. Gilbert, Karen Page, Elena Peeva, Michael S. Vincent, Jean S. Beebe

{"title":"Zimlovisertib、Ritlecitinib和Tofacitinib单独或联合治疗中重度类风湿关节炎和甲氨蝶呤反应不足患者的疗效和安全性","authors":"Spencer I. Danto, Mikhail Salganik, Anindita Banerjee, Pawel Hrycaj, Irina Jashi, Negin Shojaee, Ravi Shankar P. Singh, Steven A. Gilbert, Karen Page, Elena Peeva, Michael S. Vincent, Jean S. Beebe","doi":"10.1002/art.43184","DOIUrl":null,"url":null,"abstract":"To evaluate the efficacy and safety of zimlovisertib (interleukin-1 receptor-associated kinase 4 inhibitor) in combination with ritlecitinib (a Janus kinase [JAK] 3 and tyrosine kinase expressed in hepatocellular carcinoma [TEC] kinase family inhibitors) or tofacitinib (a JAK inhibitor) vs tofacitinib alone.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"183 1","pages":""},"PeriodicalIF":11.4000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety of Zimlovisertib, Ritlecitinib and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate\",\"authors\":\"Spencer I. Danto, Mikhail Salganik, Anindita Banerjee, Pawel Hrycaj, Irina Jashi, Negin Shojaee, Ravi Shankar P. Singh, Steven A. Gilbert, Karen Page, Elena Peeva, Michael S. Vincent, Jean S. Beebe\",\"doi\":\"10.1002/art.43184\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"To evaluate the efficacy and safety of zimlovisertib (interleukin-1 receptor-associated kinase 4 inhibitor) in combination with ritlecitinib (a Janus kinase [JAK] 3 and tyrosine kinase expressed in hepatocellular carcinoma [TEC] kinase family inhibitors) or tofacitinib (a JAK inhibitor) vs tofacitinib alone.\",\"PeriodicalId\":129,\"journal\":{\"name\":\"Arthritis & Rheumatology\",\"volume\":\"183 1\",\"pages\":\"\"},\"PeriodicalIF\":11.4000,\"publicationDate\":\"2025-04-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Arthritis & Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/art.43184\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arthritis & Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/art.43184","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

评价zimlovisertib（白细胞介素-1受体相关激酶4抑制剂）联合利来替尼（一种Janus激酶[JAK] 3和酪氨酸激酶表达于肝癌[TEC]激酶家族抑制剂）或托法替尼（一种JAK抑制剂）与单独使用托法替尼的疗效和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacy and Safety of Zimlovisertib, Ritlecitinib and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate

To evaluate the efficacy and safety of zimlovisertib (interleukin-1 receptor-associated kinase 4 inhibitor) in combination with ritlecitinib (a Janus kinase [JAK] 3 and tyrosine kinase expressed in hepatocellular carcinoma [TEC] kinase family inhibitors) or tofacitinib (a JAK inhibitor) vs tofacitinib alone.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Arthritis & Rheumatology RHEUMATOLOGY-

CiteScore

20.90

自引率

3.00%

发文量

371

期刊介绍： Arthritis & Rheumatology is the official journal of the American College of Rheumatology and focuses on the natural history, pathophysiology, treatment, and outcome of rheumatic diseases. It is a peer-reviewed publication that aims to provide the highest quality basic and clinical research in this field. The journal covers a wide range of investigative areas and also includes review articles, editorials, and educational material for researchers and clinicians. Being recognized as a leading research journal in rheumatology, Arthritis & Rheumatology serves the global community of rheumatology investigators and clinicians.